[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"complement-3-glomerulopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:complement-3-glomerulopathy":55},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100054117",false,"NCT07598448","A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain","Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain","ROUTE-C3G","Inclusion criteria:\n\n1. Adult patients (≥18 years).\n2. Biopsy-confirmed C3G.\n3. Patients who have received at least one dose of iptacopan through an EAP from October 2020 to June 2025.\n\nExclusion criteria:\n\n1\\. Patients treated with iptacopan through an EAP for indications other than C3G.","ALL","18 Years","100 Years",{"count":20,"type":21},35,"ESTIMATED","OBSERVATIONAL","This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.",[25],"Complement 3 Glomerulopathy",[25,27,28,29,30,31],"C3G","Iptacopan","Factor B inhibition","Alternative Complement Pathway","Early Access Program","NOT_YET_RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":21},"2026-08-23",{"date":40,"type":21},"2026-12-15",{"name":42,"class":43},"Novartis Pharmaceuticals","INDUSTRY",{"id":45,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":47,"keywords":48,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":52,"completionDateStruct":53,"leadSponsor":54,"locationsCount":4},"100638991",{"count":20,"type":21},[25],[25,27,28,29,30,31],"2026-06-29",{"date":51,"type":36},"2026-06-30",{"date":38,"type":21},{"date":40,"type":21},{"name":42,"class":43},""]